Survival Increased in Nasopharyngeal Cancer Patients by Concurrent Chemo and Radiation Regimen

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov.

A phase III study has revealed that the combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal cancer (NPC). The results are published in the Nov. 4 issue of the the Journal of the National Cancer Institute.

Nasopharyngeal carcinoma is endemic in Southern China and Southeast Asia, where radiotherapy (RT) has been the primary treatment. Although the National Comprehensive Cancer Network (NCCN) recommends concurrent chemo-radiotherapy (CCRT) for stage II disease, evidence regarding its efficacy is weak, and this has not been defined as a primary endpoint in phase III trials.

Oral Cancer | Mouth Cancer - Types, Causes, Symptoms, Diagnosis, Treatment & Prevention
Oral cancer is a cancer that develops in any part of the mouth. It is more common in men over 40.

To determine whether or not combined chemotherapy and radiotherapy confers survival benefit to stage II NPC patients, Qui-Yan Chen, M.D., Ph.D., of the Sun Yat-sen University Cancer Center in the People's Republic of China, and colleagues, conducted a phase III trial of patients randomly assigned to receive either radiation therapy (114 patients) or combined chemotherapy and radiation (116 patients).

They also found that after a median follow-up of 60 months, 22.8% of patients in the radiation group had disease progression, compared to 11.2% in the concurrent therapy group. The researchers found that 5-year overall survival, progression-free survival, and distant metastasis-free survival were statistically significantly higher in the concurrent therapy group compared with the group receiving radiation alone.

The authors conclude that based on the results of this trial, which they believe to be the first phase III trial to compare CCRT and RT, the NCCN guidelines are reasonable. They hypothesize that early-stage disease may have a smaller distant tumor bulk, and thus CCRT may be more effective in eradicating distant micro-metastases. Although patients in the combined therapy group experienced more toxic side effects than patients who only received radiotherapy, the regimen was overall well tolerated when the chemotherapy drug dose was reduced.

About Cancer in Women
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.

Chen et al write, "In summary, we think that the optimal choice for early-stage NPC is cisplatin, at a weekly dose of 30 mg/m2, for both an optimal chemotherapy effect to eradicate small distant tumors and to ensure NPC patient compliance."

Peritoneal Cancer – Types – Symptoms and Signs – Diagnosis - Treatment
Peritoneal cancer is a rare cancer that develops in the peritoneum. Peritoneal cancers may be primary or secondary and symptoms of peritoneal cancer are vague.

Source-Eurekalert

Pancreatic Cancer - All About the Disease, its Diagnosis and Management
Pancreatic cancer often involves its exocrine part. It grows aggressively, and often detected late. Treatment options include surgery, radiation and chemotherapy.